In a report issued on March 31, Ed Arce from H.C. Wainwright maintained a Buy rating on Genfit SA (GNFT), with a price target of $58.00. The company’s shares closed last Wednesday at $14.50.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 6.3% and a 35.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Genfit SA with a $46.00 average price target, a 217.2% upside from current levels. In a report released yesterday, B.Riley FBR also reiterated a Buy rating on the stock with a $34.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.25 and a one-year low of $9.73. Currently, Genfit SA has an average volume of 51.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.
